Prostate Cancer News and Research

Latest Prostate Cancer News and Research

TQ can suppress growth of aggressive PCa cell lines: Researchers

Researchers at the Tulane University School of Medicine, in New Orleans, LA, have demonstrated that thymoquinone a major component of black seed oil (Nigella sativa) can suppress the growth of several aggressive prostate cancer cell lines, in vitro. Although previous studies have shown the anti-proliferative effects of TQ in different types of cancers, the molecular mechanism of this effect of TQ had not been delineated.

2 Jun 2010

Men who refuse surgery for prostate cancer have 51% overall survival rate: Study

Men who refuse surgery for prostate cancer and instead opt for "watchful waiting" - monitoring cancer progression without undergoing treatment - have a significantly worse long-term survival rate than those patients that choose radiotherapy, according to researchers at Henry Ford Hospital in Detroit.

2 Jun 2010

Cancer patients should find ways to be physically active during and after treatment: New national guidelines

Cancer patients who've been told to rest and avoid exercise can - and should - find ways to be physically active both during and after treatment, according to new national guidelines. Kathryn Schmitz, PhD, MPH, an associate professor of Epidemiology and Biostatistics and a member of the Abramson Cancer Center at the University of Pennsylvania School of Medicine, will present these guidelines at an educational session at the 2010 meeting of the American Society of Clinical Oncology, aimed at making cancer exercise rehabilitation programs as common as those offered to people who have had heart attacks or undergone cardiac surgery.

2 Jun 2010

Study results show calcium consumption increases prostate cancer risk in Chinese

Among Chinese men, calcium consumption — even at relatively low levels and from non-dairy food sources such as soy, grains and green vegetables — may increase prostate cancer risk, according to results published in Cancer Research, a journal of the American Association for Cancer Research.

2 Jun 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that two oral podium presentations on the company's lead candidate, PRX302, will be made at the 2010 Annual Meeting of the American Urological Association (AUA). These presentations will include six month data from the Phase 2b clinical study of PRX302 called TRIUMPH, in patients with moderate to severe benign prostatic hyperplasia (BPH).

1 Jun 2010

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

Dendreon Corporation today announced the presentation of safety data from the integrated analysis of four randomized PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.

1 Jun 2010

Elekta acquires Resonant Medical

Elekta today announced the acquisition of Resonant Medical Inc., Montreal Canada. Through this acquisition, Elekta adds exciting new solutions for image guidance as well as highly skilled R&D resources in the field of oncology imaging and motion management.

From Elekta 1 Jun 2010

IMRT avoids xerostomia, but effectiveness on controlling cancer unclear

An advanced type of cancer radiation is more successful than traditional radiation in avoiding "dry mouth" when treating head and neck cancers, but it is unknown whether the treatment is better or worse at reducing the size of tumors, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

31 May 2010

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical Center will present their latest research findings at the American Urological Association Annual Meeting in San Francisco, May 29 to June 3.

31 May 2010

Misonix announces sale of all rights to HIFU technology, HIFU related assets to USHIFU

Misonix, Inc., a developer of minimally invasive ultrasonic medical device technology, which is used in Europe for the ablation of tumors and worldwide for acute health conditions, today announced the sale to USHIFU, LLC of all of the rights to the High Intensity Focused Ultrasound technology previously obtained from Focus Surgery, Inc., a wholly owned subsidiary of USHIFU, together with other HIFU related assets.

29 May 2010

EDAP to showcase Ablatherm-HIFU technology and Sonolith i-sys lithotripter at AUA 2010 Annual Meeting

EDAP TMS SA, the global leader in therapeutic ultrasound, today announced it will have a strong presence in both the exhibition and the scientific program at the American Urological Association (AUA) 2010 Annual Meeting, being held May 29 – June 3, 2010 in San Francisco. EDAP will showcase its Ablatherm-HIFU technology and Sonolith i-sys lithotripter at its exhibition booth # 1938 of the Moscone Convention Center.

29 May 2010

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

29 May 2010

US HIFU acquires Sonatherm 600 medical device from Misonix

USHIFU, LLC (US HIFU), a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies and manufacturer of the Sonablate® 500 (Sonablate) medical device, announces the acquisition of certain Misonix HIFU assets and European distribution rights. In addition, through its transaction with Misonix, US HIFU acquires the Sonatherm® 600 medical device, a laparoscopic HIFU system used to ablate certain soft tissues.

29 May 2010

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

28 May 2010

IMRT leads to fewer cases of xerostomia than other types of radiation: AHRQ report

28 May 2010

Amgen announces European approval of Prolia

Amgen Inc. today announced that the European Commission (EC) has granted marketing authorization for Prolia® (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

28 May 2010

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.

28 May 2010

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Oregon Health & Science University is partnering with the University of Oregon and Harvard Medical School to expedite basic science research into new and existing drugs and compounds that may prevent the complications associated with Fanconi anemia, an inherited condition that can lead to bone marrow failure and cancer.

28 May 2010

$Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy$

Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy

GTx, Inc. today announced that additional study results from the Phase III clinical trial evaluating toremifene 80 mg for the prevention of fractures in men with prostate cancer on androgen deprivation therapy will be presented at the 2010 Annual Meeting of the American Urological Association being held in San Francisco May 29-June 3.

27 May 2010

Abnormal androgen signaling in ovaries cause female infertility

Male sex hormones, such as testosterone, have well defined roles in male reproduction and prostate cancer. What may surprise many is that they also play an important role in female fertility. A new study finds that the presence and activity of male sex hormones in the ovaries helps regulate female fertility, likely by controlling follicle growth and development and preventing deterioration of follicles that contain growing eggs.

27 May 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

TQ can suppress growth of aggressive PCa cell lines: Researchers

Men who refuse surgery for prostate cancer have 51% overall survival rate: Study

Cancer patients should find ways to be physically active during and after treatment: New national guidelines

Study results show calcium consumption increases prostate cancer risk in Chinese

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

Elekta acquires Resonant Medical

IMRT avoids xerostomia, but effectiveness on controlling cancer unclear

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

Misonix announces sale of all rights to HIFU technology, HIFU related assets to USHIFU

EDAP to showcase Ablatherm-HIFU technology and Sonolith i-sys lithotripter at AUA 2010 Annual Meeting

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

US HIFU acquires Sonatherm 600 medical device from Misonix

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

IMRT leads to fewer cases of xerostomia than other types of radiation: AHRQ report

Amgen announces European approval of Prolia

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy

Abnormal androgen signaling in ovaries cause female infertility

What to know about prostate cancer eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in